Skip to content

Vsevolod Katritch

8 papers in the library · 1,376 citations · publishing 2013-2024

Papers

Sort Most recent Most cited

Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.

Nature Communications September 20, 2024 Václav Havel, Andrew C Kruegel, Benjamin Bechand et al. 18 citations

Ibogaine and its main metabolite noribogaine provide important molecular prototypes for markedly different treatment of substance use disorders and co-morbid mental health illnesses. However, these compounds present a cardiac safety risk and a highly complex molecular mechanism. We introduce a class of iboga alkaloids - termed oxa-iboga - defined as benzofuran-containing iboga analogs and...

Ligand and G-protein selectivity in the κ-opioid receptor.

Nature May 1, 2023 Jianming Han, Jingying Zhang, Antonina L. Nazarova et al. 79 citations

The κ-opioid receptor (KOR) represents a highly desirable therapeutic target for treating not only pain but also addiction and affective disorders1. However, the development of KOR analgesics has been hindered by the associated hallucinogenic side effects2. The initiation of KOR signalling requires the Gi/o-family proteins including the conventional (Gi1, Gi2, Gi3, GoA and GoB) and...

Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs

ACS Chemical Neuroscience December 15, 2022 Michael J. Cunningham, Hailey A. Bock, Inis C. Serrano et al. 65 citations

Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. Ariadne has been tested in humans including clinical trials at Bristol-Myers Company that indicate a lack of hallucinogenic...

Novel Class of Psychedelic Iboga Alkaloids Disrupts Opioid Use

bioRxiv (Cold Spring Harbor Laboratory) July 23, 2021 Václav Havel, Andrew C Kruegel, Benjamin Bechand et al. 3 citations preprint

Abstract Substance use and related mental health epidemics are causing increasing suffering and death in diverse communities. 1,2 Despite extensive efforts focused on developing pharmacotherapies for treating substance use disorders, there is an urgent need for radically different therapeutic approaches. 3,4 Ibogaine provides an important drug prototype in this direction, as a psychoactive...

Dynamic Strategic Bond Analysis Yields a Ten-Step Synthesis of 20-nor-Salvinorin A, a Potent κ-OR Agonist.

ACS Central Science December 27, 2017 Jeremy J Roach, Yusuke Sasano, Cullen L. Schmid et al.

Salvinorin A (SalA) is a plant metabolite that agonizes the human kappa-opioid receptor (κ-OR) with high affinity and high selectivity over mu- and delta-opioid receptors. Its therapeutic potential has stimulated extensive semisynthetic studies and total synthesis campaigns. However, structural modification of SalA has been complicated by its instability, and efficient total synthesis has been...

Chemotype-selective modes of action of κ-opioid receptor agonists.

The Journal of biological chemistry November 29, 2013 Eyal Vardy, Philip D Mosier, Kevin J Frankowski et al.

The crystal structures of opioid receptors provide a novel platform for inquiry into opioid receptor function. The molecular determinants for activation of the κ-opioid receptor (KOR) were studied using a combination of agonist docking, functional assays, and site-directed mutagenesis. Eighteen positions in the putative agonist binding site of KOR were selected and evaluated for their effects...

Structural Basis for Molecular Recognition at Serotonin Receptors

Science March 22, 2013 Chong Wang, Yi Jiang, Jinming Ma et al. 522 citations

Dissecting Serotonin Receptors Serotonin receptors are the targets for many widely used drugs prescribed to treat ailments from depression to obesity and migraine headaches (see the Perspective by Palczewski and Kiser ). C. Wang et al. (p. 610 , published online 21 March) and Wacker et al. (p. 615 , published online 21 March) describe crystal structures of two members of the serotonin family of...

Structural Features for Functional Selectivity at Serotonin Receptors

Science March 21, 2013 Daniel Wacker, Chong Wang, Vsevolod Katritch et al. 689 citations

Dissecting Serotonin Receptors Serotonin receptors are the targets for many widely used drugs prescribed to treat ailments from depression to obesity and migraine headaches (see the Perspective by Palczewski and Kiser ). C. Wang et al. (p. 610 , published online 21 March) and Wacker et al. (p. 615 , published online 21 March) describe crystal structures of two members of the serotonin family of...